For a pair of small biotechs, though, sales of certain Novartis drugs were very important.
Investors in Momenta Pharmaceuticals
Enoxaparin sales in the second quarter came in at $284 million. It's a blockbuster during its current run because Novartis is the only supplier of the generic drug. We won't know Momenta's exact share of the partnership until the company releases earnings, but we can assume it'll show a substantial profit again this quarter. In the first quarter, Novartis sold $247 million worth of enoxaparin, which resulted in it handing over nearly $76 million from the profit-sharing agreement.
Next up, Momenta's investors will have to turn their eyes toward Teva Pharmaceuticals
One biotech that investors won't have to play the sneak-peek game with is Human Genome Sciences
Interested in small companies? Grab this free report from Motley Fool analysts: "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke."
Fool contributor Brian Orelli holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Teva Pharmaceutical, GlaxoSmithKline, and Momenta Pharmaceuticals. Motley Fool newsletter services have recommended buying shares of Momenta Pharmaceuticals, Teva Pharmaceutical Industries, Novartis, and GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.